Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Feuring

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
The Journal of Allergy and Clinical Immunology|October 9, 2001
The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitisB M Schmidt, M Kusma, M Feuring, et al.
Journal of Stem Cells & Regenerative Medicine|April 3, 2014
Stem cell transplantation and cardiac regeneration after myocardial infarction in SCID mice: Human MAPCs are effective and safeM Groebner, L Deindl, I Dimomeletis, et al.
European Journal of Clinical Investigation|February 27, 2004
Delayed genomic and acute nongenomic action of glucocorticosteroids in seasonal allergic rhinitisH-C Tillmann, B A Stuck, M Feuring, et al.
Leukemia|April 12, 2016
GPR56 contributes to the development of acute myeloid leukemia in miceD Daria, N Kirsten, A Muranyi, et al.
Annals of Hematology|October 24, 2000
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study GroupM Feuring-Buske, M Kneba, M Unterhalt, et al.
Blood|September 10, 1998
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II studyB Coiffier, C Haioun, N Ketterer, et al.
Critical Reviews in Oncology/Hematology|October 7, 2005
Towards a pathogenesis-oriented therapy of acute myeloid leukemiaW Hiddemann, K Spiekermann, C Buske, et al.
Leukemia|January 23, 2009
The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemiaS Thoene, V P S Rawat, B Heilmeier, et al.
Leukemia|July 13, 2007
AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemiaF Schneider, S K Bohlander, S Schneider, et al.
Leukemia|February 19, 2014
The leukemogenicity of Hoxa9 depends on alternative splicingC R Stadler, N Vegi, M A Mulaw, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
The Journal of Allergy and Clinical Immunology|October 9, 2001
The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitisB M Schmidt, M Kusma, M Feuring, et al.
Journal of Stem Cells & Regenerative Medicine|April 3, 2014
Stem cell transplantation and cardiac regeneration after myocardial infarction in SCID mice: Human MAPCs are effective and safeM Groebner, L Deindl, I Dimomeletis, et al.
European Journal of Clinical Investigation|February 27, 2004
Delayed genomic and acute nongenomic action of glucocorticosteroids in seasonal allergic rhinitisH-C Tillmann, B A Stuck, M Feuring, et al.
Leukemia|April 12, 2016
GPR56 contributes to the development of acute myeloid leukemia in miceD Daria, N Kirsten, A Muranyi, et al.
Annals of Hematology|October 24, 2000
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study GroupM Feuring-Buske, M Kneba, M Unterhalt, et al.
Blood|September 10, 1998
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II studyB Coiffier, C Haioun, N Ketterer, et al.
Critical Reviews in Oncology/Hematology|October 7, 2005
Towards a pathogenesis-oriented therapy of acute myeloid leukemiaW Hiddemann, K Spiekermann, C Buske, et al.
Leukemia|January 23, 2009
The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemiaS Thoene, V P S Rawat, B Heilmeier, et al.
Leukemia|July 13, 2007
AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemiaF Schneider, S K Bohlander, S Schneider, et al.
Leukemia|February 19, 2014
The leukemogenicity of Hoxa9 depends on alternative splicingC R Stadler, N Vegi, M A Mulaw, et al.
Pageof 8